Articles by Sergio Garcia

How Small Biotechs Should Protect Their Interests During Mergers and Acquisitions

Early-stage companies need to assess whether a potential deal might unduly encumber the value of their intellectual property
Jan 1, 2008
By: Sergio Garcia

Strategic alliances and partnering deals were a big biotech news story during 2006—with deal values setting an all time record of over $23 billion for the year. The strategic partnering trend continues during 2007 and in this column we present some frequently asked questions and answers about the merger and acquisition (M&A) activity in the life sciences sector.

IP Briefs: IP Due Diligence: Key to Success in M&A Transactions

Properly conducted IP due diligence provides a potential acquirer with information that is critical in assessing the value, price, or other key elements of the transaction
Mar 1, 2007
By: Sergio Garcia

Although IP due diligence is relevant to virtually any transaction between biotech companies, a detailed investigation into IP assets is particularly critical to M&A transactions.

Legal Forum: Putting the "Co" in Development and Promotion: The New Biotech-Pharma Collaborations

Companies considering partnering arrangements must do financial and operational due diligence to ensure the success of the collaborations
Aug 1, 2006
By: Sergio Garcia

Wyeth today relies on biotech product revenue to drive approximately 25% of its revenues.